Results 21 to 30 of about 4,480,566 (269)
Rationale for the Successful Management of EDTA Chelation Therapy in Human Burden by Toxic Metals [PDF]
BioMed Research International, 2016 Exposure to environmental and occupational toxicants is responsible for adverse effects on human health. Chelation therapy is the only procedure able to remove toxic metals from human organs and tissue, aiming to treat damage related to acute and/or ...
Maria Elena Ferrero
openalex +2 more sources
Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with nontransfusion-dependent thalassemia syndromes [PDF]
Drug Design, Development and Therapy, 2016 The prevalence rate of thalassemia, which is endemic in Southeast Asia, the Middle East, and the Mediterranean, exceeds 100,000 live births per year. There are many genetic variants in thalassemia with different pathological severity, ranging from a mild
Cappellini, MD +4 more
core +2 more sources
Predictors of Non-adherence to iron chelation therapy in pediatric thalassemia patients
Journal of Rawalpindi Medical College, 2022 Objective: This study was conducted to identify predictors of non-adherence to iron chelation therapy among children suffering from β-thalassemia major across different treatment regimens.
Muniba Kanwal +3 more
doaj +1 more source
Chelation Therapy in Patients With Cardiovascular Disease: A Systematic Review
Journal of the American Heart Association : Cardiovascular and Cerebrovascular Disease, 2021 Background EDTA is an intravenous chelating agent with high affinity to divalent cations (lead, cadmium, and calcium) that may be beneficial in the treatment of cardiovascular disease (CVD).
Filippo Ravalli +6 more
semanticscholar +1 more source
Haematologica, 2023 CALYPSO (clinicaltrials gov. Identifier: NCT02435212), a randomized, open-label, multicenter, phase II study evaluated the compliance, clinical benefits, and safety of deferasirox granules and dispersible tablets (DT) in pediatric patients with iron ...
Ali T. Taher +8 more
doaj +1 more source
Journal of Applied Hematology, 2023 BACKGROUND: Thalassemia is severe public health problem in Iraq and other nearby countries, represents about 75% of all hemogloniopathy with prevalence and incidence 36/100.000 and 34/100.000 respectively.
Mohammed Ali Al-Jabory +2 more
doaj +1 more source
Current Biomedical Use of Copper Chelation Therapy
International Journal of Molecular Sciences, 2020 Copper is an essential microelement that plays an important role in a wide variety of biological processes. Copper concentration has to be finely regulated, as any imbalance in its homeostasis can induce abnormalities.
S. Baldari +2 more
semanticscholar +1 more source
Journal of Internal Medicine, 1997 Desferrioxamine (DFX) remains the most effective and safe iron chelator for treatment of patients with transfusional iron overload. It is usually given by intermittent subcutaneous infusions for 8–12 h on 4–6 days weekly using a battery‐driven pump. Disposable balloon infusers provide a suitable method of giving continuous subcutaneous infusions with ...
A.V. Hoffbrand, B. Wonke
openaire +3 more sources
Медицинский совет, 2016 Iron overload (RV) is a condition caused by excessive intake of iron, and in the absence of the specific mechanisms for its excretion - excessive accumulation in tissues and their subsequent lesion leading to functional organ failure [1].
M. V. Krasolnikova
doaj +1 more source
Blood-brain barrier transport kinetics of NOTA-modified proteins : the somatropin case [PDF]
, 2020 BACKGROUND: Chemical modifications such as PEG, polyamine and radiolabeling on proteins can alter their pharmacokinetic behaviour and their blood-brain barrier (BBB) transport characteristics. NOTA, i.e. 1,4,7-triazacyclononane-1,4,7-triacetic acid, is a
Bracke, Nathalie +7 more
core +1 more source